✦ LIBER ✦

The CYP2C8 inhibitor gemfibrozil does not affect the pharmacokinetics of zafirlukast

✍ Scribed by Tiina Karonen; Pertti J. Neuvonen; Janne T. Backman

Publisher: Springer
Year: 2010
Tongue: English
Weight: 141 KB
Volume: 67
Category: Article
ISSN: 0031-6970
DOI: 10.1007/s00228-010-0908-0

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Montelukast and zafirlukast do not affec

Montelukast and zafirlukast do not affect the pharmacokinetics of the CYP2C8 substrate pioglitazone

✍ Tiina Jaakkola; Janne T. Backman; Mikko Neuvonen; Mikko Niemi; Pertti J. Neuvone 📂 Article 📅 2006 🏛 Springer 🌐 English ⚖ 148 KB

The CYP2C8 inhibitor gemfibrozil does no

The CYP2C8 inhibitor gemfibrozil does not increase the plasma concentrations of zopiclone

✍ Aleksi Tornio; Pertti J. Neuvonen; Janne T. Backman 📂 Article 📅 2006 🏛 Springer 🌐 English ⚖ 191 KB

Stereoselective interaction between the

Stereoselective interaction between the CYP2C8 inhibitor gemfibrozil and racemic ibuprofen

✍ Aleksi Tornio; Mikko Niemi; Pertti J. Neuvonen; Janne T. Backman 📂 Article 📅 2007 🏛 Springer 🌐 English ⚖ 185 KB

The pharmacokinetics of ketobemidone are

The pharmacokinetics of ketobemidone are not affected by CYP2D6 or CYP2C19 phenotype

✍ Ayman Al-Shurbaji; Juliette Säwe 📂 Article 📅 2002 🏛 Springer 🌐 English ⚖ 84 KB

Pioglitazone, an in vitro inhibitor of C

Pioglitazone, an in vitro inhibitor of CYP2C8 and CYP3A4, does not increase the plasma concentrations of the CYP2C8 and CYP3A4 substrate repaglinide

✍ Lauri I. Kajosaari; Tiina Jaakkola; Pertti J. Neuvonen; Janne T. Backman 📂 Article 📅 2006 🏛 Springer 🌐 English ⚖ 164 KB

Hepatic fibrosis does not affect the pha

Hepatic fibrosis does not affect the pharmacokinetics of 5-fluorouracil in rats

✍ Masashi Nagata; Yumi Hidaka; Kinta Hatakeyama; Yohei Kawano; Tomomi Iwakiri; Man 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 213 KB 👁 1 views